US05338F3064
US05338F3064
Avalo Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 59.000 | 441.000 | 86.6% |
| Cost of Revenue | -- | -366.000 | -- |
| Gross Profit | 59.000 | 807.000 | 92.7% |
| 72.984.000 | 41.678.000 | 75.1% | |
| Operating Income | -72.925.000 | -40.871.000 | 78.4% |
| Pretax Income | -78.094.000 | -35.015.000 | 123.0% |
| Net Income Common Stockholders | -78.259.000 | -35.129.000 | 122.8% |
| -- | -- | -- | |
| -- | -- | -- |